GeoVax Labs Secures $2.5 Million in Registered Direct Offering to Advance Clinical Programs

GeoVax Labs, Inc. has entered into a securities purchase agreement with healthcare-focused institutional investors for a registered direct offering totaling approximately $2.5 million in gross proceeds. The clinical-stage biotechnology company will sell 3,968,256 shares of common stock and warrants to purchase up to 11,904,768 additional shares at a combined price of $0.63 per unit. The financing represents a critical capital infusion for advancing the company's pipeline of immunotherapies and vaccines against cancer and infectious diseases.

The offering's significance lies in its timing and purpose, as GeoVax intends to use the net proceeds to advance multiple product candidates through research and development, manufacturing, and clinical studies. This funding comes at a pivotal moment for the company, which has three Phase 2 clinical trials underway for its next-generation COVID-19 vaccine, GEO-CM04S1. The vaccine is being evaluated as both a primary vaccine for immunocompromised patients and a booster for various patient populations, addressing critical gaps in current COVID-19 protection.

Roth Capital Partners served as sole placement agent for the transaction, which was conducted under a shelf registration statement previously filed with the Securities and Exchange Commission. Investors can access detailed offering documents through the SEC's website at https://www.sec.gov, where electronic copies of the final prospectus supplement and accompanying prospectus will be available.

Beyond its COVID-19 program, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company also maintains a robust development pipeline including a vaccine targeting Mpox and smallpox, which has received regulatory guidance allowing progression directly to Phase 3 clinical evaluation. This strategic funding enables continued momentum across these diverse therapeutic areas while supporting general corporate purposes and working capital needs.

The capital raise demonstrates investor confidence in GeoVax's technology platform and clinical strategy during a period of significant advancement across multiple programs. The company's ability to secure institutional investment reflects the potential market opportunity for its differentiated vaccine approaches and oncology therapies. With this financing, GeoVax strengthens its position to generate meaningful clinical data from ongoing trials while maintaining operational flexibility to pursue additional development opportunities.